Company: NDRA
Filing Date: 2025-11-14
Form Type: 10-Q
Source: 0001213900-25-110887
Chunk: 4

Company: ENDRA Life Sciences Inc.
Filing Date: 2025-11-14
Form: 10-Q
Item: Part I, Item 1
Chunk 4
---
 -  
     -  
     -  
     -  
     (3,858,201) 
     (3,858,201)
  
    Balance as of September 30,2025 
     17.488  
    $-  
     -  
    $-  
     786,902  
    $77  
    $107,467,603  
    $-  
    $(107,296,300) 
    $171,380 

3

Three Months Ended September 30,2024

    Series A Convertible  
    Series B Convertible  

    Additional  

    Total 

    Preferred Stock  
    Preferred Stock  
    Common stock  
     Paid in  
    Stock  
    Accumulated  
    Stockholders’ 

    Shares  
    Amount  
    Shares  
    Amount  
    Shares  
    Amount  
    Capital  
    Payable  
    Deficit  
    Equity 
  
    Balance as of June 30, 2024 
     17.488  
     -  
     -  
    $-  
     41,394  
    $4  
    $105,928,915  
     27  
    $(96,935,005) 
    $8,993,941 
  
    Common stock issued for warrant exercise 
     -  
     -  
     -  
     -  
     493,469  
     49  
     1,634  
     -  
     -  
     1,683 
  
    Fair value of vested stock options 
     -  
     -  
     -  
     -  
     -  
     -  
     (36,848) 
     -  
     -  
     (36,848)
  
    Stock payable towards preference dividend 
     -  
     -  
     -  
     -  
     -  
        
     27  
     (27) 
     -  
     - 
  
    Net loss 
     -  
     -  
     -  
     -